FDA OKs First Antibody-Drug Conjugate for Platinum-Resistant Ovarian Cancer
(MedPage Today) -- The FDA granted accelerated approval for the antibody-drug conjugate (ADC) mirvetuximab soravtansine (Elahere) for folate receptor α (FRα)-positive platinum-resistant ovarian cancer.
The action makes mirvetuximab the...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Cancer | Cancer & Oncology | International Medicine & Public Health | Ovarian Cancer | Ovaries